1. Yang X#, Zhong J#, Yu Z#, Zhuo M, Zhang M, Chen R, Xia X, Zhao J. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. BMC Cancer. 2021 Oct 15;21(1):1107. （IF 4.430）#共同第一作者
2. Wang L, Zhao J, An T, Wang Y, Zhuo M, Wu M, Wang Z, Li J, Yang X, Chen H, Zhong J*. Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. Front Oncol. 2020 Jul 16;10:1137. （IF 6.244）*通讯作者
3. Zhong J, Zheng QW, Zhao J, Wang ZP, Wu MN, Zhuo ML, Wang YY, Li JJ, Yang X, Chen HX, An TT. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer]. Zhonghua Zhong Liu Za Zhi. 2020 Sep 23;42(9):771-776.
4. Zhong J, Guo Z, Fan L, Zhao X, Zhao B, Cao Z, Cheng L, Shi Y, Li X, Zhang Y, An T, Wu M, Wang Y, Zhuo M, Li J, Yang X, Chen H, Jia B, Zhao J. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy. Thorac Cancer. 2019 Nov;10(11):2088-2095.（IF 3.500）
5. Zhong J, Zheng Q, An T, Zhao J, Wu M, Wang Y, Zhuo M, Li J, Zhao X, Yang X, Jia B, Chen H, Dong Z, Wang J, Chi Y, Zhai X, Wang Z. Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. Thorac Cancer. 2019 Sep;10(9):1788-1797. (IF 3.500)
6. Zhong J, Zheng Q, Gao E, Dong Z, Zhao J, An T, Wu M, Zhuo M, Wang Y, Li J, Wang S, Yang X, Chen H, Jia B, Wang J, Wang Z.Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma.Thorac Cancer. 2018 Feb;9(2):291-297.(IF 3.500)
7. Zhong J, Li L, Wang Z, Bai H, Gai F, Duan J, Zhao J, Zhuo M, Wang Y, Wang S, Zang W, Wu M, An T, Rao G, Zhu G, Wang J.Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs).J Thorac Oncol. 2017 Dec;12(12):1766-1778.
